A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy
Luminari, S., Pinto, A., Puccini, B., D’Arpino, A., Omodeo Salè, E., Bellone, M., Pradelli, L., & Sabinot, A. ClinicoEconomics and outcomes research : CEOR, 17, 335–348
Cost-effectiveness of treatments for presymptomatic newborn patients with spinal muscular atrophy and two or three copies of the survival motor neuron 2 gene in Italy
Valentini I, Ghetti G, Pane M, Rumi F, Di Brino E, Basile M, Pistillo GM, Bischof M. Eur J Health Econ. 2025 Jun 26
179P Genomic profiling in hepatocellular carcinoma: A real-world retrospective analysis
F. Salani, F.R. Ponziani, F. Piscaglia, U. Malapelle, B. Daniele, C. Porta, L. Pradelli, E. De Fiore, G. Masi, L. Rimassa, A. Casadei Gardini. Annals of Oncology, Volume 36, S75 – S76
Retifanlimab Vs Avelumab in Patients with Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy
Gianni Ghetti, Camilla Porta, Massimiliano Povero. Farmeconomia. Health economics and therapeutic pathways 2025; 26(1): 29-39
Real-World Outcomes of Single-Inhaler Triple Therapy Prescribed by General Practitioners in Managing Chronic Obstructive Pulmonary Disease: A Systematic Literature Review
Odonde L, Pradelli L, Micheletto C. Farmeconomia Health Econ Ther Pathw 2025; 26
The clinical impact of conventional therapies for adults and adolescents suffering from eosinophilic esophagitis, a type 2 inflammatory chronic disease, and their economic consequences in Italy: Systematic literature review and meta-analysis.
Canonica GW, Mazziotti G, Repici A, et al. J Allergy Clin Immunol Glob 2025; 4;
Lipids in parenteral nutrition – expert consensus statements: translating guidelines into clinical practice.
Martindale RG, Calder PC, Cogle SV, et al. Clin Nutr Open Sci 2025; 0;
